Compare Fastly Inc (FSLY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastly Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Fastly Inc trades at $24.6 (market cap $4.32B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Fastly Inc and Travere Therapeutics Inc. Common Stock are close in size by market cap, and Fastly Inc is more actively traded (5,665,889 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold Fastly Inc for 26 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FSLY | TVTX | |
|---|---|---|
Market Cap | $4.32B | $4.88B |
Volume | 5,665,889 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $33.50 | $67.52 |
52-Week Low | $7.86 | $26.79 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $4.38B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastly (FSLY) trades at $25.00, down 5.41% over the past day, with a bullish technical signal from moving averages and support at $25. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.15 exceeding expectations, while revenue growth is robust at 23% year-over-year. However, net income remains negative, and cash flow trends show volatility, with a net outflow of $105.61 million in 2025. Recent news highlights insider selling by the CTO but also positive coverage of AI-driven growth potential.
The outlook for FSLY is mixed, with opportunities from AI infrastructure demand and revenue targets up to $1.3 billion by 2029, but risks include persistent losses, high valuation multiples, and competitive pressures. Analyst consensus is a 'Hold' with a $28.33 price target, suggesting limited near-term upside from current levels amid execution challenges.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
